890839-26-6 Usage
Abbreviation
BDSA
Physical appearance
White to off-white crystalline solid
Usage
Pharmaceutical research and drug development
Chemical class
Benzazepinones
Receptor selectivity
Potent and selective antagonist for the dopamine D1 receptor
Targeted disorders
Neuropsychiatric disorders
Preclinical studies
Shown promising results for potential use in the treatment of cognitive and memory deficits
Neurotransmitter modulation
Investigated for its role in modulating the release of certain neurotransmitters
Analgesic potential
Investigated as a potential analgesic agent
Therapeutic potential
Versatile chemical with significant therapeutic potential
Research status
Subject of active research in the field of medicinal chemistry
Check Digit Verification of cas no
The CAS Registry Mumber 890839-26-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,9,0,8,3 and 9 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 890839-26:
(8*8)+(7*9)+(6*0)+(5*8)+(4*3)+(3*9)+(2*2)+(1*6)=216
216 % 10 = 6
So 890839-26-6 is a valid CAS Registry Number.
890839-26-6Relevant articles and documents
A Cascade of acid-promoted c-o bond cleavage and redox reactions: From oxa-bridged benzazepines to benzazepinones
Zhang, Yuewei,Yang, Fengzhi,Zheng, Lianyou,Dang, Qun,Bai, Xu
, p. 6041 - 6043 (2014)
A sequence of C-O bond cleavage and redox reactions in oxa-bridged azepines was realized under acid promoted conditions. This protocol provides an atom-economical and straightforward approach to access benzo[b]azepin-5(2H)-ones in high yields. The formal synthesis of tolvaptan was achieved by exploiting this new transformation.
Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
-
Page/Page column 19, (2008/06/13)
Compounds that are antagonists of the VR1 receptor, having formula (I) [image] or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A1, A2, A3, A4, R7, R8, R9, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.
